RecruitingNCT06779916

Autophagy/Apoptosis Balance in Placental Vascular Pathologies

Study of the Autophagy/Apoptosis Balance in Placental Vascular Pathologies


Sponsor

Centre Hospitalier Universitaire de Nīmes

Enrollment

50 participants

Start Date

May 2, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Pregnancy increases the risk of thrombosis. Placenta-mediated diseases are a risk factor for cardiovascular pathologies and can lead to maternal-fetal morbidity and mortality. It is essential to understand the cellular and molecular mechanisms of dysfunctions at the vascular-placental interface so that systemic vascular risk can be characterized and, ultimately, screened for, on the basis of new markers (targeted preventive management). Deregulated autophagy could be the starting point for cell death by apoptosis or necrosis leading to complications. The pathophysiological mechanisms involved in trophoblast apoptosis are incompletely described. This project follows on from the GrossAuTop-1 study, which investigated the intra- and inter-individual variability of autophagy and apoptosis activities in women during pregnancy. The aim of this project is to study autophagy and apoptosis activities specifically in women developing a placental vascular complication during pregnancy.


Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is examining tissue from the placenta (the organ that nourishes the baby during pregnancy) in women who develop serious pregnancy complications such as preeclampsia (dangerous high blood pressure) or fetal growth restriction (when the baby does not grow enough). Researchers want to understand how cell death processes in the placenta contribute to these conditions. **You may be eligible if...** - You are pregnant and have developed preeclampsia and/or intrauterine growth restriction - You are being cared for and delivering at the Nimes University Hospital - You have health insurance coverage - You are able to give informed consent **You may NOT be eligible if...** - You are carrying twins or multiples - You had high blood pressure or protein in your urine before getting pregnant - You are currently participating in another interventional drug study - You are under legal protection or guardianship - You cannot provide informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTBlood test

16 blood samples (16 tubes, i.e. 55.3 ml) will be taken at inclusion. Pregnant women will be seen every month as part of their pregnancy follow-up, and blood (11 tubes, i.e. 35.5 ml) and urine samples will be taken at each follow-up visit. At delivery, a systematic blood sample will be taken as part of the usual care, and an additional 11 tubes of blood (35.5 ml) will be taken.

DIAGNOSTIC_TESTUrine test

Urine samples will be taken at the inclusion visit and at each follow-up visit.


Locations(1)

Nimes University Hospital

Nîmes, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06779916


Related Trials